Z-LEHD-fmk Options
The key conclusion stage was the safety and tolerability of sifalimumab. Procedure-emergent adverse functions (AEs) and serious AEs (SAEs) and their severity, final result, and any partnership into the research medication have been recorded via the investigator all through the analyze. AEs were deemed very likely to be connected to study medication